Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for ...

The addition of tiragolumab to Tecentriq in patients with advanced PD-L1-high NSCLC failed to improve overall survival in a Phase III trial.

Severe infection with Covid-19 has been found to produce a powerful cancer-fighting cell that can shrink tumors.

The phase 3 SKYSCRAPER-01 trial of tiragolumab and atezolizumab in PD-L1-high non–small cell lung cancer did not meet its primary end point of overall survival.

The acquisition announcement came alongside the reveal of a Phase III failure for Roche’s TIGIT asset tiragolumab, which when ...

CNSide can aid the diagnosis and management of leptomeningeal metastases in patients with cancer, a new study suggests.

The global trial enrolled patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors had a ...

A cancer treatment from Roche failed to improve survival in a major lung cancer study, a result that will stoke doubts about ...

Roche’s Skyscraper-01 has fallen down. The phase 3 trial found adding the TIGIT candidate tiragolumab to a checkpoint ...

Genentech announced that the Phase III SKYSCRAPER-01 study, which evaluated tiragolumab combined with Tecentriq (atezolizumab) versus ...

locally advanced or metastatic non-small cell lung cancer (NSCLC). SKYSCRAPER-01 is a global Phase III, randomized, ...

A trial testing tiragolumab in small cell lung cancer failed in 2022 and then, a few months later, data from SKYSCRAPER-01 ...